President Trump said all generic drugs imported into the United States will have zero tariffs for two years from Aug. 1, 2026. Thereafter tariffs will be raised to 100% for one year and then to 200% thereafter; the move is aimed at repatriating generic drug production and penalizing firms that fail to establish domestic production facilities and equipment within the required timeframe. Existing tariff and trade policies for patented, brand and innovative drugs will remain unchanged.
U.S. construction of pharmaceutical manufacturing capacity is proceeding at an unprecedented scale nationwide, he said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments